130 related articles for article (PubMed ID: 10486371)
1. Increased activation of lymphocytes infiltrating primary colorectal cancers following immunisation with the anti-idiotypic monoclonal antibody 105AD7.
Maxwell-Armstrong CA; Durrant LG; Robins RA; Galvin AM; Scholefield JH; Hardcastle JD
Gut; 1999 Oct; 45(4):593-8. PubMed ID: 10486371
[TBL] [Abstract][Full Text] [Related]
2. Clinical evidence that the human monoclonal anti-idiotypic antibody 105AD7, delays tumor growth by stimulating anti-tumor T-cell responses.
Buckley DT; Robins AR; Durrant LG
Hum Antibodies Hybridomas; 1995; 6(2):68-72. PubMed ID: 7492753
[TBL] [Abstract][Full Text] [Related]
3. A neoadjuvant clinical trial in colorectal cancer patients of the human anti-idiotypic antibody 105AD7, which mimics CD55.
Durrant LG; Maxwell-Armstrong C; Buckley D; Amin S; Robins RA; Carmichael J; Scholefield JH
Clin Cancer Res; 2000 Feb; 6(2):422-30. PubMed ID: 10690519
[TBL] [Abstract][Full Text] [Related]
4. 105Ad7 cancer vaccine stimulates anti-tumour helper and cytotoxic T-cell responses in colorectal cancer patients but repeated immunisations are required to maintain these responses.
Durrant LG; Buckley DJ; Robins RA; Spendlove I
Int J Cancer; 2000 Jan; 85(1):87-92. PubMed ID: 10585589
[TBL] [Abstract][Full Text] [Related]
5. Induction of cellular immune responses by a murine monoclonal anti-idiotypic antibody recognizing the 791Tgp72 antigen expressed on colorectal, gastric and ovarian human tumours.
Durrant LG; Doran M; Austin EB; Robins RA
Int J Cancer; 1995 Mar; 61(1):62-6. PubMed ID: 7705934
[TBL] [Abstract][Full Text] [Related]
6. Randomized double-blind phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer.
Maxwell-Armstrong CA; Durrant LG; Buckley TJ; Scholefield JH; Robins RA; Fielding K; Monson JR; Guillou P; Calvert H; Carmichael J; Hardcastle JD
Br J Cancer; 2001 Jun; 84(11):1443-6. PubMed ID: 11384090
[TBL] [Abstract][Full Text] [Related]
7. Low doses of 105AD7 cancer vaccine preferentially stimulate anti-tumor T-cell immunity.
Durrant LG; Buckley DJ; Spendlove I; Robins RA
Hybridoma; 1997 Feb; 16(1):23-6. PubMed ID: 9085124
[TBL] [Abstract][Full Text] [Related]
8. Human monoclonal anti-idiotypic antibody to the tumour-associated antibody 791T/36.
Austin EB; Robins RA; Durrant LG; Price MR; Baldwin RW
Immunology; 1989 Aug; 67(4):525-30. PubMed ID: 2788611
[TBL] [Abstract][Full Text] [Related]
9. Studies using the anti-idiotypic monoclonal antibody 105AD7 in patients with primary and advanced colorectal cancer.
Maxwell-Armstrong C
Ann R Coll Surg Engl; 2002 Sep; 84(5):314-8. PubMed ID: 12398121
[TBL] [Abstract][Full Text] [Related]
10. A neoadjuvant/adjuvant randomized trial of colorectal cancer patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55.
Ullenhag GJ; Spendlove I; Watson NF; Indar AA; Dube M; Robins RA; Maxwell-Armstrong C; Scholefield JH; Durrant LG
Clin Cancer Res; 2006 Dec; 12(24):7389-96. PubMed ID: 17121873
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcome of colorectal cancer patients treated with human monoclonal anti-idiotypic antibody.
Denton GW; Durrant LG; Hardcastle JD; Austin EB; Sewell HF; Robins RA
Int J Cancer; 1994 Apr; 57(1):10-4. PubMed ID: 8150527
[TBL] [Abstract][Full Text] [Related]
12. Antitumor immune response and interleukin 2 production induced in colorectal cancer patients by immunization with human monoclonal anti-idiotypic antibody.
Robins RA; Denton GW; Hardcastle JD; Austin EB; Baldwin RW; Durrant LG
Cancer Res; 1991 Oct; 51(19):5425-9. PubMed ID: 1913661
[TBL] [Abstract][Full Text] [Related]
13. Enhanced cell-mediated tumor killing in patients immunized with human monoclonal antiidiotypic antibody 105AD7.
Durrant LG; Buckley TJ; Denton GW; Hardcastle JD; Sewell HF; Robins RA
Cancer Res; 1994 Sep; 54(18):4837-40. PubMed ID: 8069847
[TBL] [Abstract][Full Text] [Related]
14. Immune responses in advanced colorectal cancer following repeated intradermal vaccination with the anti-CEA murine monoclonal antibody, PR1A3: results of a phase I study.
Zbar AP; Thomas H; Wilkinson RW; Wadhwa M; Syrigos KN; Ross EL; Dilger P; Allen-Mersh TG; Kmiot WA; Epenetos AA; Snary D; Bodmer WF
Int J Colorectal Dis; 2005 Sep; 20(5):403-14. PubMed ID: 15864608
[TBL] [Abstract][Full Text] [Related]
15. Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue.
Chaput N; Louafi S; Bardier A; Charlotte F; Vaillant JC; Ménégaux F; Rosenzwajg M; Lemoine F; Klatzmann D; Taieb J
Gut; 2009 Apr; 58(4):520-9. PubMed ID: 19022917
[TBL] [Abstract][Full Text] [Related]
16. Infiltration of mononuclear inflammatory cells into primary colorectal carcinomas: an immunohistological analysis.
Håkansson L; Adell G; Boeryd B; Sjögren F; Sjödahl R
Br J Cancer; 1997; 75(3):374-80. PubMed ID: 9020482
[TBL] [Abstract][Full Text] [Related]
17. A therapeutic human anti-idiotypic antibody mimics CD55 in three distinct regions.
Spendlove L; Li L; Potter V; Christiansen D; Loveland BE; Durrant LG
Eur J Immunol; 2000 Oct; 30(10):2944-53. PubMed ID: 11069077
[TBL] [Abstract][Full Text] [Related]
18. Interleukin 2 restores CD3-zeta chain expression but fails to generate tumour-specific lytic activity in tumour-infiltrating lymphocytes derived from human colorectal hepatic metastases.
Yoong KF; Adams DH
Br J Cancer; 1998 Apr; 77(7):1072-81. PubMed ID: 9569042
[TBL] [Abstract][Full Text] [Related]
19. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.
Woo EY; Chu CS; Goletz TJ; Schlienger K; Yeh H; Coukos G; Rubin SC; Kaiser LR; June CH
Cancer Res; 2001 Jun; 61(12):4766-72. PubMed ID: 11406550
[TBL] [Abstract][Full Text] [Related]
20. T-cell responses in osteosarcoma patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55.
Ullenhag GJ; Spendlove I; Watson NF; Kallmeyer C; Pritchard-Jones K; Durrant LG
Clin Immunol; 2008 Aug; 128(2):148-54. PubMed ID: 18508409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
